Loading...

William Oh, MD

Address155 N Fresno St
Fresno CA 93701
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. McNeel DG, Bander NH, Beer TM, Drake CG, Fong L, Harrelson S, Kantoff PW, Madan RA, Oh WK, Peace DJ, Petrylak DP, Porterfield H, Sartor O, Shore ND, Slovin SF, Stein MN, Vieweg J, Gulley JL. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. J Immunother Cancer. 2016; 4:92. PMID: 28031820.
      View in: PubMed
    2. Tsao CK, Sfakianos J, Liaw B, Gimpel-Tetra K, Kemeny M, Bulone L, Shahin M, Oh WK, Galsky MD. Phase II Trial of Abiraterone Acetate Plus Prednisone in Black Men With Metastatic Prostate Cancer. Oncologist. 2016 Oct 14. PMID: 27742908.
      View in: PubMed
    3. Galsky MD, Stensland K, Sfakianos JP, Mehrazin R, Diefenbach M, Mohamed N, Tsao CK, Boffetta P, Wiklund P, Oh WK, Mazumdar M, Ferket B. Comparative Effectiveness of Treatment Strategies for Bladder Cancer With Clinical Evidence of Regional Lymph Node Involvement. J Clin Oncol. 2016 Aug 1; 34(22):2627-35. PMID: 27269939.
      View in: PubMed
    4. Heck MM, Thalgott M, Schmid SC, Oh WK, Gong Y, Wang L, Zhu J, Seitz AK, Porst D, Höppner M, Retz M, Gschwend JE, Nawroth R. A 2-Gene Panel Derived From Prostate Cancer-Enhanced Transcripts in Whole Blood Is Prognostic for Survival and Predicts Treatment Benefit in Metastatic Castration-Resistant Prostate Cancer. Prostate. 2016 Sep; 76(13):1160-8. PMID: 27198487.
      View in: PubMed
    5. Galsky MD, Stensland KD, Moshier E, Sfakianos JP, McBride RB, Tsao CK, Casey M, Boffetta P, Oh WK, Mazumdar M, Wisnivesky JP. Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer. J Clin Oncol. 2016 Mar 10; 34(8):825-32. PMID: 26786930.
      View in: PubMed
    6. Mirza H, Laptook AR, Oh W, Vohr BR, Stoll BJ, Kandefer S, Stonestreet BS. Effects of indomethacin prophylaxis timing on intraventricular haemorrhage and patent ductus arteriosus in extremely low birth weight infants. Arch Dis Child Fetal Neonatal Ed. 2016 Sep; 101(5):F418-22. PMID: 26733540.
      View in: PubMed
    7. Mercer JS, Erickson-Owens DA, Vohr BR, Tucker RJ, Parker AB, Oh W, Padbury JF. Effects of Placental Transfusion on Neonatal and 18 Month Outcomes in Preterm Infants: A Randomized Controlled Trial. J Pediatr. 2016 Jan; 168:50-55.e1. PMID: 26547399.
      View in: PubMed
    8. Williams ES, Rodriquez-Bravo V, Chippada-Venkata U, De Ia Iglesia-Vicente J, Gong Y, Galsky M, Oh W, Cordon-Cardo C, Domingo-Domenech J. Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells. J Vis Exp. 2015; (105). PMID: 26555435.
      View in: PubMed
    9. Galsky MD, Hahn NM, Wong B, Lee KM, Argiriadi P, Albany C, Gimpel-Tetra K, Lowe N, Shahin M, Patel V, Tsao CK, Oh WK. Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma. Cancer Chemother Pharmacol. 2015 Dec; 76(6):1259-65. PMID: 26464352.
      View in: PubMed
    10. Wang L, Gong Y, Chippada-Venkata U, Heck MM, Retz M, Nawroth R, Galsky M, Tsao CK, Schadt E, de Bono J, Olmos D, Zhu J, Oh WK. A robust blood gene expression-based prognostic model for castration-resistant prostate cancer. BMC Med. 2015; 13:201. PMID: 26297150; PMCID: PMC4546313.
    11. Shevach J, Gallagher EJ, Kochukoshy T, Gresia V, Brar M, Galsky MD, Oh WK. Concurrent Diabetes Mellitus may Negatively Influence Clinical Progression and Response to Androgen Deprivation Therapy in Patients with Advanced Prostate Cancer. Front Oncol. 2015; 5:129. PMID: 26125012; PMCID: PMC4467174.
    12. Liaw BC, Shevach J, Oh WK. Systemic therapy for the treatment of hormone-sensitive metastatic prostate cancer: from intermittent androgen deprivation therapy to chemotherapy. Curr Urol Rep. 2015 Mar; 16(3):13. PMID: 25677235.
      View in: PubMed
    13. Leiter A, Diefenbach MA, Doucette J, Oh WK, Galsky MD. Clinical trial awareness: Changes over time and sociodemographic disparities. Clin Trials. 2015 Jun; 12(3):215-23. PMID: 25673636; PMCID: PMC4667750.
    14. Galsky MD, Stensland KD, McBride RB, Latif A, Moshier E, Oh WK, Wisnivesky J. Geographic accessibility to clinical trials for advanced cancer in the United States. JAMA Intern Med. 2015 Feb; 175(2):293-5. PMID: 25437434.
      View in: PubMed
    15. Tsao CK, Gray KP, Nakabayashi M, Evan C, Kantoff PW, Huang J, Galsky MD, Pomerantz M, Oh WK. Patients with Biopsy Gleason 9 and 10 Prostate Cancer Have Significantly Worse Outcomes Compared to Patients with Gleason 8 Disease. J Urol. 2015 Jul; 194(1):91-7. PMID: 25623747.
      View in: PubMed
    16. Casey MF, Gross T, Wisnivesky J, Stensland KD, Oh WK, Galsky MD. The Impact of Regionalization of Cystectomy on Racial Disparities in Bladder Cancer Care. J Urol. 2015 Jul; 194(1):36-41. PMID: 25623748.
      View in: PubMed
    17. Gong Y, Chippada-Venkata UD, Galsky MD, Huang J, Oh WK. Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer. Prostate. 2015 May; 75(6):616-27. PMID: 25560638.
      View in: PubMed
    18. Petrylak DP, Gandhi JG, Clark WR, Heath E, Lin J, Oh WK, Agus DB, Carthon B, Moran S, Kong N, Suri A, Bargfrede M, Liu G. Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer. Invest New Drugs. 2015 Apr; 33(2):397-408. PMID: 25556680; PMCID: PMC4390470 [Available on 04/01/16].
    19. Sonpavde G, Wang CG, Galsky MD, Oh WK, Armstrong AJ. Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC). BJU Int. 2015 Jul; 116(1):17-29. PMID: 25046451.
      View in: PubMed
    20. Courtney KD, Manola JB, Elfiky AA, Ross R, Oh WK, Yap JT, Van den Abbeele AD, Ryan CW, Beer TM, Loda M, Priolo C, Kantoff P, Taplin ME. A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer. Clin Genitourin Cancer. 2015 Apr; 13(2):113-23. PMID: 25450031; PMCID: PMC4418946 [Available on 04/01/16].
    21. Leiter A, Sablinski T, Diefenbach M, Foster M, Greenberg A, Holland J, Oh WK, Galsky MD. Use of crowdsourcing for cancer clinical trial development. J Natl Cancer Inst. 2014 Oct; 106(10). PMID: 25217580.
      View in: PubMed
    22. Stensland KD, McBride RB, Latif A, Wisnivesky J, Hendricks R, Roper N, Boffetta P, Hall SJ, Oh WK, Galsky MD. Adult cancer clinical trials that fail to complete: an epidemic? J Natl Cancer Inst. 2014 Sep; 106(9). PMID: 25190726.
      View in: PubMed
    23. Agarwal N, Apolo AB, Tsao CK, Lee KM, Godbold JH, Soto R, Poole A, Gimpel-Tetra K, Lowe N, Oh WK, Galsky MD. Phase Ib/II trial of gemcitabine, cisplatin, and lenalidomide as first-line therapy in patients with metastatic urothelial carcinoma. Oncologist. 2014 Sep; 19(9):915-6. PMID: 25052451; PMCID: PMC4153455.
    24. Galsky MD, Posner M, Holcombe RF, Lee KM, Misiukiewicz K, Tsao CK, Godbold J, Soto R, Gimpel-Tetra K, Lowe N, Oh WK. Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Sep; 74(3):465-71. PMID: 25023489; PMCID: PMC4146643.
    25. Galsky MD, Oh WK. Mind the gap: efficacy versus effectiveness and pivotal prostate cancer clinical trial demographics. Cancer. 2014 Oct 1; 120(19):2944-5. PMID: 24965362.
      View in: PubMed
    26. Tsao CK, Cutting E, Martin J, Oh WK. The role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer. Ther Adv Urol. 2014 Jun; 6(3):97-104. PMID: 24883107; PMCID: PMC4003844.
    27. Yu EY, Oh WK. The metastatic castration-resistant prostate cancer treatment paradigm: more choices, more questions. Asian J Androl. 2014 May-Jun; 16(3):331-3. PMID: 24759585; PMCID: PMC4023355.
    28. Saenger Y, Magidson J, Liaw B, de Moll E, Harcharik S, Fu Y, Wassmann K, Fisher D, Kirkwood J, Oh WK, Friedlander P. Blood mRNA expression profiling predicts survival in patients treated with tremelimumab. Clin Cancer Res. 2014 Jun 15; 20(12):3310-8. PMID: 24721645.
      View in: PubMed
    29. Tsao CK, Small A, Hall S, Oh WK, Galsky MD, Buckstein M, Stock R, Ali G, Morris GJ. T2 muscle-invasive bladder cancer. Semin Oncol. 2014 Apr; 41(2):e11-8. PMID: 24787300.
      View in: PubMed
    30. Morgan CJ, Oh WK, Naik G, Galsky MD, Sonpavde G. Impact of prednisone on toxicities and survival in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol. 2014 Jun; 90(3):253-61. PMID: 24500033.
      View in: PubMed
    31. Tsao CK, Galsky MD, Oh WK. Is metastatic prostate cancer changing, and how will we know it? It's time for standard nomenclature for nonosseous metastases in clinical trials of patients with metastatic castration resistant prostate cancer. Eur Urol. 2014 Aug; 66(2):184-5. PMID: 24433812.
      View in: PubMed
    32. Doctor SM, Tsao CK, Godbold JH, Galsky MD, Oh WK. Is prostate cancer changing?: evolving patterns of metastatic castration-resistant prostate cancer. Cancer. 2014 Mar 15; 120(6):833-9. PMID: 25302607.
      View in: PubMed
    33. Sivendran S, Latif A, McBride RB, Stensland KD, Wisnivesky J, Haines L, Oh WK, Galsky MD. Adverse event reporting in cancer clinical trial publications. J Clin Oncol. 2014 Jan 10; 32(2):83-9. PMID: 24323037.
      View in: PubMed
    34. Galsky MD, Moshier E, Krege S, Lin CC, Hahn N, Ecke T, Sonpavde G, Pond G, Godbold J, Oh WK, Bamias A. Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy. Urol Oncol. 2014 Jan; 32(1):48.e1-8. PMID: 24055428.
      View in: PubMed
    35. Stark AR, Carlo WA, Vohr BR, Papile LA, Saha S, Bauer CR, Oh W, Shankaran S, Tyson JE, Wright LL, Poole WK, Das A, Stoll BJ, Fanaroff AA, Korones SB, Ehrenkranz RA, Stevenson DK, Peralta-Carcelen M, Wilson-Costello DE, Bada HS, Heyne RJ, Johnson YR, Lee KG, Steichen JJ. Death or neurodevelopmental impairment at 18 to 22 months corrected age in a randomized trial of early dexamethasone to prevent death or chronic lung disease in extremely low birth weight infants. J Pediatr. 2014 Jan; 164(1):34-39.e2. PMID: 23992673; PMCID: PMC4120744.
    36. Gartrell BA, Ying J, Sivendran S, Boucher KM, Choueiri TK, Sonpavde G, Oh WK, Agarwal N, Galsky MD. Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis. Target Oncol. 2014 Sep; 9(3):195-204. PMID: 23852656.
      View in: PubMed
    37. Galsky MD, Oh WK. Tumour angiogenesis: an elusive target in castration-resistant prostate cancer. Lancet Oncol. 2013 Jul; 14(8):681-2. PMID: 23742876.
      View in: PubMed
    38. Galsky MD, Krege S, Lin CC, Hahn N, Ecke T, Moshier E, Sonpavde G, Godbold J, Oh WK, Bamias A. Relationship between 6- and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapy. Cancer. 2013 Aug 15; 119(16):3020-6. PMID: 23720197.
      View in: PubMed
    39. Galsky MD, Moshier E, Krege S, Lin CC, Hahn N, Ecke T, Sonpavde G, Godbold J, Oh WK, Bamias A. Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy. Cancer. 2013 Aug 15; 119(16):3012-9. PMID: 23720216.
      View in: PubMed
    40. Sivendran S, Agarwal N, Gartrell B, Ying J, Boucher KM, Choueiri TK, Sonpavde G, Oh WK, Galsky MD. Metabolic complications with the use of mTOR inhibitors for cancer therapy. Cancer Treat Rev. 2014 Feb; 40(1):190-6. PMID: 23684373.
      View in: PubMed
    41. Haines L, Bamias A, Krege S, Lin CC, Hahn N, Ecke TH, Moshier E, Sonpavde G, Godbold J, Oh WK, Galsky MD. The impact of gender on outcomes in patients with metastatic urothelial carcinoma. Clin Genitourin Cancer. 2013 Sep; 11(3):346-52. PMID: 23673281.
      View in: PubMed
    42. Cookson MS, Roth BJ, Dahm P, Engstrom C, Freedland SJ, Hussain M, Lin DW, Lowrance WT, Murad MH, Oh WK, Penson DF, Kibel AS. Castration-resistant prostate cancer: AUA Guideline. J Urol. 2013 Aug; 190(2):429-38. PMID: 23665272.
      View in: PubMed
    43. Tsao CK, Liaw B, Yee T, Galsky MD, Oh WK. Metabolic and toxicological considerations of newly approved prostate cancer drugs. Expert Opin Drug Metab Toxicol. 2013 Jul; 9(7):835-46. PMID: 23581700.
      View in: PubMed
    44. Mirza H, Oh W, Laptook A, Vohr B, Tucker R, Stonestreet BS. Indomethacin prophylaxis to prevent intraventricular hemorrhage: association between incidence and timing of drug administration. J Pediatr. 2013 Sep; 163(3):706-10.e1. PMID: 23522865; PMCID: PMC3939677.
    45. Galsky MD, Krege S, Lin CC, Hahn N, Ecke TH, Moshier E, Sonpavde G, Godbold J, Oh WK, Bamias A. Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer. Urol Oncol. 2014 Jan; 32(1):30.e15-21. PMID: 23428534.
      View in: PubMed
    46. Tsao CK, Small AC, Kates M, Moshier EL, Wisnivesky JP, Gartrell BA, Sonpavde G, Godbold JH, Palese MA, Hall SJ, Oh WK, Galsky MD. Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis. World J Urol. 2013 Dec; 31(6):1535-9. PMID: 23223962.
      View in: PubMed
    47. Tsao CK, Gartrell BA, Oh WK, Galsky MD. Emerging personalized approaches for the management of advanced urothelial carcinoma. Expert Rev Anticancer Ther. 2012 Dec; 12(12):1537-43. PMID: 23253220.
      View in: PubMed
    48. Seng S, Liu Z, Chiu SK, Proverbs-Singh T, Sonpavde G, Choueiri TK, Tsao CK, Yu M, Hahn NM, Oh WK, Galsky MD. Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. J Clin Oncol. 2012 Dec 10; 30(35):4416-26. PMID: 23150697.
      View in: PubMed
    49. Proverbs-Singh T, Chiu SK, Liu Z, Seng S, Sonpavde G, Choueiri TK, Tsao CK, Yu M, Hahn NM, Oh WK, Galsky MD. Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis. J Natl Cancer Inst. 2012 Dec 5; 104(23):1837-40. PMID: 23093559.
      View in: PubMed
    50. Ross RW, Galsky MD, Scher HI, Magidson J, Wassmann K, Lee GS, Katz L, Subudhi SK, Anand A, Fleisher M, Kantoff PW, Oh WK. A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. Lancet Oncol. 2012 Nov; 13(11):1105-13. PMID: 23059047.
      View in: PubMed
    51. Tsao CK, Galsky MD, Small AC, Yee T, Oh WK. Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC). BJU Int. 2012 Dec; 110(11):1580-8. PMID: 22985411.
      View in: PubMed
    52. Nakabayashi M, Werner L, Courtney KD, Buckle G, Oh WK, Bubley GJ, Hayes JH, Weckstein D, Elfiky A, Sims DM, Kantoff PW, Taplin ME. Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer. BJU Int. 2012 Dec; 110(11):1729-35. PMID: 22928480.
      View in: PubMed
    53. Vinjamoori AH, Jagannathan JP, Shinagare AB, Taplin ME, Oh WK, Van den Abbeele AD, Ramaiya NH. Atypical metastases from prostate cancer: 10-year experience at a single institution. AJR Am J Roentgenol. 2012 Aug; 199(2):367-72. PMID: 22826398.
      View in: PubMed
    54. Small AC, Tsao CK, Moshier EL, Gartrell BA, Wisnivesky JP, Godbold JH, Smith CB, Sonpavde G, Oh WK, Galsky MD. Prevalence and characteristics of patients with metastatic cancer who receive no anticancer therapy. Cancer. 2012 Dec 1; 118(23):5947-54. PMID: 22707387.
      View in: PubMed
    55. Wadhawan R, Oh W, Vohr BR, Saha S, Das A, Bell EF, Laptook A, Shankaran S, Stoll BJ, Walsh MC, Higgins R. Spontaneous intestinal perforation in extremely low birth weight infants: association with indometacin therapy and effects on neurodevelopmental outcomes at 18-22 months corrected age. Arch Dis Child Fetal Neonatal Ed. 2013 Mar; 98(2):F127-32. PMID: 22684157; PMCID: PMC3753803.
    56. Tsao CK, Small AC, Moshier EL, Gartrell BA, Wisnivesky JP, Sonpavde G, Godbold JH, Palese MA, Hall SJ, Oh WK, Galsky MD. Trends in the use of cytoreductive nephrectomy in the United States. Clin Genitourin Cancer. 2012 Sep; 10(3):159-63. PMID: 22651971.
      View in: PubMed
    57. Sivendran S, Liu Z, Portas LJ, Yu M, Hahn N, Sonpavde G, Oh WK, Galsky MD. Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: a meta-analysis. Cancer Treat Rev. 2012 Nov; 38(7):919-25. PMID: 22651902.
      View in: PubMed
    58. Small AC, Tsao CK, Moshier EL, Gartrell BA, Wisnivesky JP, Godbold J, Sonpavde G, Palese MA, Hall SJ, Oh WK, Galsky MD. Trends and variations in utilization of nephron-sparing procedures for stage I kidney cancer in the United States. World J Urol. 2013 Oct; 31(5):1211-7. PMID: 22622394.
      View in: PubMed
    59. Small AC, Gong Y, Oh WK, Hall SJ, van Rijn CJ, Galsky MD. The emerging role of circulating tumor cell detection in genitourinary cancer. J Urol. 2012 Jul; 188(1):21-6. PMID: 22578722.
      View in: PubMed
    60. Tsao CK, Small AC, Galsky MD, Oh WK. Overcoming castration resistance in prostate cancer. Curr Opin Urol. 2012 May; 22(3):167-74. PMID: 22472508.
      View in: PubMed
    61. Galsky MD, Small AC, Tsao CK, Oh WK. Clinical development of novel therapeutics for castration-resistant prostate cancer: historic challenges and recent successes. CA Cancer J Clin. 2012 Sep-Oct; 62(5):299-308. PMID: 22535487.
      View in: PubMed
    62. Sommers R, Stonestreet BS, Oh W, Laptook A, Yanowitz TD, Raker C, Mercer J. Hemodynamic effects of delayed cord clamping in premature infants. Pediatrics. 2012 Mar; 129(3):e667-72. PMID: 22331336; PMCID: PMC3356138.
    63. Ross RW, Galsky MD, Febbo P, Barry M, Richie JP, Xie W, Fennessy FM, Bhatt RS, Hayes J, Choueiri TK, Tempany CM, Kantoff PW, Taplin ME, Oh WK. Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial. Cancer. 2012 Oct 1; 118(19):4777-84. PMID: 22282219; PMCID: PMC3791849.
    64. Tsao CK, Moshier E, Seng SM, Godbold J, Grossman S, Winston J, Oh WK, Galsky MD. Impact of the CKD-EPI equation for estimating renal function on eligibility for cisplatin-based chemotherapy in patients with urothelial cancer. Clin Genitourin Cancer. 2012 Mar; 10(1):15-20. PMID: 22130294.
      View in: PubMed
    65. Nakabayashi M, Werner L, Oh WK, Regan MM, Kantoff PW, Taplin ME. Secondary hormonal therapy in men with castration-resistant prostate cancer. Clin Genitourin Cancer. 2011 Dec; 9(2):95-103. PMID: 21958520.
      View in: PubMed
    66. Sun T, Oh WK, Jacobus S, Regan M, Pomerantz M, Freedman ML, Lee GS, Kantoff PW. The impact of common genetic variations in genes of the sex hormone metabolic pathways on steroid hormone levels and prostate cancer aggressiveness. Cancer Prev Res (Phila). 2011 Dec; 4(12):2044-50. PMID: 21900597; PMCID: PMC3773969.
    67. Carlo WA, McDonald SA, Tyson JE, Stoll BJ, Ehrenkranz RA, Shankaran S, Goldberg RN, Das A, Schendel D, Thorsen P, Skogstrand K, Hougaard DM, Oh W, Laptook AR, Duara S, Fanaroff AA, Donovan EF, Korones SB, Stevenson DK, Papile LA, Finer NN, O'Shea TM, Poindexter BB, Wright LL, Ambalavanan N, Higgins RD. Cytokines and neurodevelopmental outcomes in extremely low birth weight infants. J Pediatr. 2011 Dec; 159(6):919-25.e3. PMID: 21798559; PMCID: PMC3215787.
    68. Oh WK, Galsky MD, Stadler WM, Srinivas S, Chu F, Bubley G, Goddard J, Dunbar J, Ross RW. Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer. Urology. 2011 Sep; 78(3):626-30. PMID: 21762967; PMCID: PMC3166448.
    69. Galsky MD, Seng S, Camacho LH, Chiorean EG, Mulkerin D, Hong DS, Oh WK, Bajorin DF. Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy. Clin Genitourin Cancer. 2011 Sep; 9(1):27-30. PMID: 21700509.
      View in: PubMed
    70. Tsao CK, Seng S, Oh WK, Galsky MD. Clinical development of cabazitaxel for the treatment of castration-resistant prostate cancer. Clin Med Insights Oncol. 2011; 5:163-9. PMID: 21695098; PMCID: PMC3117627.
    71. Yang M, Xie W, Mostaghel E, Nakabayashi M, Werner L, Sun T, Pomerantz M, Freedman M, Ross R, Regan M, Sharifi N, Figg WD, Balk S, Brown M, Taplin ME, Oh WK, Lee GS, Kantoff PW. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2011 Jun 20; 29(18):2565-73. PMID: 21606417; PMCID: PMC3138634.
    72. Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, Dreicer R, Vogelzang N, Sternberg CN, Bajorin DF, Bellmunt J. Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. J Clin Oncol. 2011 Jun 10; 29(17):2432-8. PMID: 21555688.
      View in: PubMed
    73. Tai S, Sun Y, Squires JM, Zhang H, Oh WK, Liang CZ, Huang J. PC3 is a cell line characteristic of prostatic small cell carcinoma. Prostate. 2011 Nov; 71(15):1668-79. PMID: 21432867; PMCID: PMC3426349.
    74. Misra D, Xie W, Regan MM, Ross RW, Lee GS, Germain D, Kantoff PW, Oh WK. Germline CAG repeat length of the androgen receptor and time to progression in patients with prostate cancer treated with androgen deprivation therapy. BJU Int. 2011 Oct; 108(7):1086-91. PMID: 21410629.
      View in: PubMed
    75. Pomerantz MM, Werner L, Xie W, Regan MM, Lee GS, Sun T, Evan C, Petrozziello G, Nakabayashi M, Oh WK, Kantoff PW, Freedman ML. Association of prostate cancer risk Loci with disease aggressiveness and prostate cancer-specific mortality. Cancer Prev Res (Phila). 2011 May; 4(5):719-28. PMID: 21367958; PMCID: PMC3811002.
    76. Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, Dreicer R, Vogelzang N, Sternberg C, Bajorin DF, Bellmunt J. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol. 2011 Mar; 12(3):211-4. PMID: 21376284.
      View in: PubMed
    77. Woo HC, Lizarda A, Tucker R, Mitchell ML, Vohr B, Oh W, Phornphutkul C. Congenital hypothyroidism with a delayed thyroid-stimulating hormone elevation in very premature infants: incidence and growth and developmental outcomes. J Pediatr. 2011 Apr; 158(4):538-42. PMID: 21232766.
      View in: PubMed
    78. Abe M, Xie W, Regan MM, King IB, Stampfer MJ, Kantoff PW, Oh WK, Chan JM. Single-nucleotide polymorphisms within the antioxidant defence system and associations with aggressive prostate cancer. BJU Int. 2011 Jan; 107(1):126-34. PMID: 20477822; PMCID: PMC3010266.
    79. Sun T, Mary LG, Oh WK, Freedman ML, Pomerantz M, Pienta KJ, Kantoff PW. Inherited variants in the chemokine CCL2 gene and prostate cancer aggressiveness in a Caucasian cohort. Clin Cancer Res. 2011 Mar 15; 17(6):1546-52. PMID: 21135144; PMCID: PMC3060307.
    80. Drzymalski DM, Oh WK, Werner L, Regan MM, Kantoff P, Tuli S. Predictors of survival in patients with prostate cancer and spinal metastasis. Presented at the 2009 Joint Spine Section Meeting. Clinical article. J Neurosurg Spine. 2010 Dec; 13(6):789-94. PMID: 21121759.
      View in: PubMed
    81. Pomerantz MM, Shrestha Y, Flavin RJ, Regan MM, Penney KL, Mucci LA, Stampfer MJ, Hunter DJ, Chanock SJ, Schafer EJ, Chan JA, Tabernero J, Baselga J, Richardson AL, Loda M, Oh WK, Kantoff PW, Hahn WC, Freedman ML. Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. PLoS Genet. 2010 Nov; 6(11):e1001204. PMID: 21085629; PMCID: PMC2978684.
    82. Anees M, Horak P, El-Gazzar A, Susani M, Heinze G, Perco P, Loda M, Lis R, Krainer M, Oh WK. Recurrence-free survival in prostate cancer is related to increased stromal TRAIL expression. Cancer. 2011 Mar 15; 117(6):1172-82. PMID: 21381010.
      View in: PubMed
    83. Penney KL, Pyne S, Schumacher FR, Sinnott JA, Mucci LA, Kraft PL, Ma J, Oh WK, Kurth T, Kantoff PW, Giovannucci EL, Stampfer MJ, Hunter DJ, Freedman ML. Genome-wide association study of prostate cancer mortality. Cancer Epidemiol Biomarkers Prev. 2010 Nov; 19(11):2869-76. PMID: 20978177; PMCID: PMC3197738.
    84. Oh WK, Vargas R, Jacobus S, Leitzel K, Regan MM, Hamer P, Pierce K, Brown-Shimer S, Carney W, Ali SM, Kantoff PW, Lipton A. Elevated plasma tissue inhibitor of metalloproteinase-1 levels predict decreased survival in castration-resistant prostate cancer patients. Cancer. 2011 Feb 1; 117(3):517-25. PMID: 20862742.
      View in: PubMed
    85. Sun T, Lee GS, Oh WK, Pomerantz M, Yang M, Xie W, Freedman ML, Kantoff PW. Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population. Clin Cancer Res. 2010 Nov 1; 16(21):5244-51. PMID: 20855462; PMCID: PMC2970725.
    86. Galsky MD, Dritselis A, Kirkpatrick P, Oh WK. Cabazitaxel. Nat Rev Drug Discov. 2010 Sep; 9(9):677-8. PMID: 20811375.
      View in: PubMed
    87. Sun T, Lee GS, Werner L, Pomerantz M, Oh WK, Kantoff PW, Freedman ML. Inherited variations in AR, ESR1, and ESR2 genes are not associated with prostate cancer aggressiveness or with efficacy of androgen deprivation therapy. Cancer Epidemiol Biomarkers Prev. 2010 Jul; 19(7):1871-8. PMID: 20615892; PMCID: PMC3755451.
    88. Harrison MR, Hahn NM, Pili R, Oh WK, Hammers H, Sweeney C, Kim K, Perlman S, Arnott J, Sidor C, Wilding G, Liu G. A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). Invest New Drugs. 2011 Dec; 29(6):1465-74. PMID: 20499131; PMCID: PMC3042040.
    89. Elfiky AA, Cho DC, McDermott DF, Rosenberg JE, Fortner B, Antràs L, Chen K, Sheng Duh M, Jayawant SS, Oh WK, Atkins MB, Choueiri TK. Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma. Urol Oncol. 2011 Nov-Dec; 29(6):756-63. PMID: 20451414.
      View in: PubMed
    90. Bellmunt J, Oh WK. Castration-resistant prostate cancer: new science and therapeutic prospects. Ther Adv Med Oncol. 2010 May; 2(3):189-207. PMID: 21789134; PMCID: PMC3126017.
    91. Choueiri TK, Regan MM, Rosenberg JE, Oh WK, Clement J, Amato AM, McDermott D, Cho DC, Atkins MB, Signoretti S. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. BJU Int. 2010 Sep; 106(6):772-8. PMID: 20230385.
      View in: PubMed
    92. Oh WK, Landrum MB, Lamont EB, McNeil BJ, Keating NL. Does oral antiandrogen use before leuteinizing hormone-releasing hormone therapy in patients with metastatic prostate cancer prevent clinical consequences of a testosterone flare? Urology. 2010 Mar; 75(3):642-7. PMID: 19962733.
      View in: PubMed
    93. Taplin ME, Regan MM, Ko YJ, Bubley GJ, Duggan SE, Werner L, Beer TM, Ryan CW, Mathew P, Tu SM, Denmeade SR, Oh WK, Sartor O, Mantzoros CS, Rittmaster R, Kantoff PW, Balk SP. Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. Clin Cancer Res. 2009 Nov 15; 15(22):7099-105. PMID: 19887483; PMCID: PMC3644858.
    94. Choueiri TK, Duh MS, Clement J, Brick AJ, Rogers MJ, Kwabi C, Shah K, Percy AG, Antràs L, Jayawant SS, Chen K, Wang ST, Luka A, Neary MP, McDermott D, Oh WK. Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review. BJU Int. 2010 May; 105(9):1247-54. PMID: 19863525.
      View in: PubMed
    95. Nakabayashi M, Oh WK, Jacobus S, Regan MM, Taplin ME, Kantoff PW, Rosenberg JE. Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer. BJU Int. 2010 May; 105(10):1392-6. PMID: 19863532.
      View in: PubMed
    96. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009 Dec 1; 27(34):5794-9. PMID: 19826129.
      View in: PubMed
    97. Sartor O, Nakabayashi M, Taplin ME, Ross RW, Kantoff PW, Balk SP, Oh WK. Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone. Clin Genitourin Cancer. 2009 Oct; 7(3):E90-2. PMID: 19815488.
      View in: PubMed
    98. Aggarwal R, Weinberg V, Small EJ, Oh W, Rushakoff R, Ryan CJ. The mechanism of action of estrogen in castration-resistant prostate cancer: clues from hormone levels. Clin Genitourin Cancer. 2009 Oct; 7(3):E71-6. PMID: 19815485.
      View in: PubMed
    99. Jia L, Landan G, Pomerantz M, Jaschek R, Herman P, Reich D, Yan C, Khalid O, Kantoff P, Oh W, Manak JR, Berman BP, Henderson BE, Frenkel B, Haiman CA, Freedman M, Tanay A, Coetzee GA. Functional enhancers at the gene-poor 8q24 cancer-linked locus. PLoS Genet. 2009 Aug; 5(8):e1000597. PMID: 19680443; PMCID: PMC2717370.
    100. Pomerantz MM, Beckwith CA, Regan MM, Wyman SK, Petrovics G, Chen Y, Hawksworth DJ, Schumacher FR, Mucci L, Penney KL, Stampfer MJ, Chan JA, Ardlie KG, Fritz BR, Parkin RK, Lin DW, Dyke M, Herman P, Lee S, Oh WK, Kantoff PW, Tewari M, McLeod DG, Srivastava S, Freedman ML. Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res. 2009 Jul 1; 69(13):5568-74. PMID: 19549893; PMCID: PMC2884104.
    101. Chan JM, Oh WK, Xie W, Regan MM, Stampfer MJ, King IB, Abe M, Kantoff PW. Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancer. J Clin Oncol. 2009 Aug 1; 27(22):3577-83. PMID: 19528373; PMCID: PMC2720077.
    102. Penney KL, Salinas CA, Pomerantz M, Schumacher FR, Beckwith CA, Lee GS, Oh WK, Sartor O, Ostrander EA, Kurth T, Ma J, Mucci L, Stanford JL, Kantoff PW, Hunter DJ, Stampfer MJ, Freedman ML. Evaluation of 8q24 and 17q risk loci and prostate cancer mortality. Clin Cancer Res. 2009 May 1; 15(9):3223-30. PMID: 19366828; PMCID: PMC2878092.
    103. Choueiri TK, Xie W, D'Amico AV, Ross RW, Hu JC, Pomerantz M, Regan MM, Taplin ME, Kantoff PW, Sartor O, Oh WK. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Cancer. 2009 Mar 1; 115(5):981-7. PMID: 19152438; PMCID: PMC2931827.
    104. Morris MJ, Basch EM, Wilding G, Hussain M, Carducci MA, Higano C, Kantoff P, Oh WK, Small EJ, George D, Mathew P, Beer TM, Slovin SF, Ryan C, Logothetis C, Scher HI. Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research. Clin Genitourin Cancer. 2009 Jan; 7(1):51-7. PMID: 19213669; PMCID: PMC3394090.
    105. Sher DJ, Mantzoros C, Jacobus S, Regan MM, Lee GS, Oh WK. Absence of relationship between steroid hormone levels and prostate cancer tumor grade. Urology. 2009 Feb; 73(2):356-61; discussion 361-2. PMID: 19036418.
      View in: PubMed
    106. Rosenberg JE, Oh WK. What is the current status of second-line chemotherapy for castration-resistant prostate cancer? Nat Clin Pract Urol. 2008 Dec; 5(12):650-1. PMID: 18936787.
      View in: PubMed
    107. Simon RA, di Sant'Agnese PA, Huang LS, Xu H, Yao JL, Yang Q, Liang S, Liu J, Yu R, Cheng L, Oh WK, Palapattu GS, Wei J, Huang J. CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers. Hum Pathol. 2009 Feb; 40(2):252-8. PMID: 18835619.
      View in: PubMed
    108. Sher DJ, Oh WK, Jacobus S, Regan MM, Lee GS, Mantzoros C. Relationship between serum adiponectin and prostate cancer grade. Prostate. 2008 Oct 1; 68(14):1592-8. PMID: 18646046.
      View in: PubMed
    109. Schurko B, Oh WK. Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer. Nat Clin Pract Oncol. 2008 Sep; 5(9):506-7. PMID: 18648352.
      View in: PubMed
    110. Oh W, Perritt R, Shankaran S, Merritts M, Donovan EF, Ehrenkranz RA, O'Shea TM, Tyson JE, Laptook AR, Das A, Higgins RD. Association between urinary lactate to creatinine ratio and neurodevelopmental outcome in term infants with hypoxic-ischemic encephalopathy. J Pediatr. 2008 Sep; 153(3):375-8. PMID: 18534246; PMCID: PMC2953792.
    111. Taplin ME, Manola J, Oh WK, Kantoff PW, Bubley GJ, Smith M, Barb D, Mantzoros C, Gelmann EP, Balk SP. A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones. BJU Int. 2008 May; 101(9):1084-9. PMID: 18399827.
      View in: PubMed
    112. Ross RW, Xie W, Regan MM, Pomerantz M, Nakabayashi M, Daskivich TJ, Sartor O, Taplin ME, Kantoff PW, Oh WK. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. Cancer. 2008 Mar 15; 112(6):1247-53. PMID: 18293426.
      View in: PubMed
    113. Ross RW, Oh WK, Xie W, Pomerantz M, Nakabayashi M, Sartor O, Taplin ME, Regan MM, Kantoff PW, Freedman M. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol. 2008 Feb 20; 26(6):842-7. PMID: 18281655.
      View in: PubMed
    114. Ross RW, Beer TM, Jacobus S, Bubley GJ, Taplin ME, Ryan CW, Huang J, Oh WK. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer. 2008 Feb 1; 112(3):521-6. PMID: 18085595.
      View in: PubMed
    115. Nakabayashi M, Sartor O, Jacobus S, Regan MM, McKearn D, Ross RW, Kantoff PW, Taplin ME, Oh WK. Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer. BJU Int. 2008 Feb; 101(3):308-12. PMID: 18184327.
      View in: PubMed
    116. Keating NL, O'Malley AJ, McNaughton-Collins M, Oh WK, Smith MR. Use of androgen deprivation therapy for metastatic prostate cancer in older men. BJU Int. 2008 May; 101(9):1077-83. PMID: 18190632; PMCID: PMC2900629.
    117. Xie W, Nakabayashi M, Regan MM, Oh WK. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase. Cancer. 2007 Dec 15; 110(12):2709-15. PMID: 17960608.
      View in: PubMed
    118. Avigan DE, Vasir B, George DJ, Oh WK, Atkins MB, McDermott DF, Kantoff PW, Figlin RA, Vasconcelles MJ, Xu Y, Kufe D, Bukowski RM. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother. 2007 Oct; 30(7):749-61. PMID: 17893567.
      View in: PubMed
    119. Mathew P, Thall PF, Bucana CD, Oh WK, Morris MJ, Jones DM, Johnson MM, Wen S, Pagliaro LC, Tannir NM, Tu SM, Meluch AA, Smith L, Cohen L, Kim SJ, Troncoso P, Fidler IJ, Logothetis CJ. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res. 2007 Oct 1; 13(19):5816-24. PMID: 17908974.
      View in: PubMed
    120. Daskivich TJ, Regan MM, Oh WK. Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy. Urology. 2007 Sep; 70(3):527-31. PMID: 17905110.
      View in: PubMed
    121. Pomerantz M, Manola J, Taplin ME, Bubley G, Inman M, Lowell J, Beard C, Kantoff PW, Oh WK. Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer. J Urol. 2007 Jun; 177(6):2146-50. PMID: 17509304.
      View in: PubMed
    122. Oh WK, Proctor K, Nakabayashi M, Evan C, Tormey LK, Daskivich T, Antràs L, Smith M, Neary MP, Duh MS. The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid. Cancer. 2007 Mar 15; 109(6):1090-6. PMID: 17311345.
      View in: PubMed
    123. Nakabayashi M, Ling J, Xie W, Regan MM, Oh WK. Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer. Cancer J. 2007 Mar-Apr; 13(2):125-9. PMID: 17476141.
      View in: PubMed
    124. Oh WK, Tay MH, Huang J. Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer? Cancer. 2007 Feb 1; 109(3):477-86. PMID: 17186531.
      View in: PubMed
    125. Clyman RI, Saha S, Jobe A, Oh W. Indomethacin prophylaxis for preterm infants: the impact of 2 multicentered randomized controlled trials on clinical practice. J Pediatr. 2007 Jan; 150(1):46-50.e2. PMID: 17188612; PMCID: PMC1849955.
    126. Daskivich TJ, Regan MM, Oh WK. Prostate specific antigen doubling time calculation: not as easy as 1, 2, 4. J Urol. 2006 Nov; 176(5):1927-37. PMID: 17070213.
      View in: PubMed
    127. Sternberg CN, Krainer M, Oh WK, Bracarda S, Bellmunt J, Ozen H, Zlotta A, Beer TM, Oudard S, Rauchenwald M, Skoneczna I, Borner MM, Fitzpatrick JM. The medical management of prostate cancer: a multidisciplinary team approach. BJU Int. 2007 Jan; 99(1):22-7. PMID: 16956362.
      View in: PubMed
    128. Nakabayashi M, Xie W, Regan MM, Jackman DM, Kantoff PW, Oh WK. Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer. Cancer. 2006 Sep 1; 107(5):975-81. PMID: 16862573.
      View in: PubMed
    129. Michaelson MD, Kaufman DS, Kantoff P, Oh WK, Smith MR. Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. Cancer. 2006 Aug 1; 107(3):530-5. PMID: 16804927.
      View in: PubMed
    130. Nakabayashi M, Bartlett RA, Oh WK. Treatment of bicalutamide-induced gynecomastia with breast-reduction surgery in prostate cancer. J Clin Oncol. 2006 Jun 20; 24(18):2958-9. PMID: 16782932.
      View in: PubMed
    131. Smith MR, Manola J, Kaufman DS, Oh WK, Bubley GJ, Kantoff PW. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol. 2006 Jun 20; 24(18):2723-8. PMID: 16782912.
      View in: PubMed
    132. Gilligan T, Oh WK, Kantoff PW. Carboplatin for stage I seminoma. J Clin Oncol. 2006 Jun 20; 24(18):2971-2; author reply e32-3. PMID: 16782940.
      View in: PubMed
    133. Oh WK, Hayes J, Evan C, Manola J, George DJ, Waldron H, Donovan M, Varner J, Orechia J, Katcher B, Lu D, Nevins A, Wright RL, Tormey L, Talcott J, Rubin MA, Loda M, Sellers WR, Richie JP, Kantoff PW, Weeks J. Development of an integrated prostate cancer research information system. Clin Genitourin Cancer. 2006 Jun; 5(1):61-6. PMID: 16859581.
      View in: PubMed
    134. Lin HC, Su BH, Oh W. Oral probiotics prevent necrotizing enterocolitis. J Pediatr. 2006 Jun; 148(6):849; author reply 850. PMID: 16769410.
      View in: PubMed
    135. Oh WK, Manola J, Babcic V, Harnam N, Kantoff PW. Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes. Urology. 2006 Jun; 67(6):1235-40. PMID: 16765185.
      View in: PubMed
    136. Daskivich TJ, Oh WK. Recent progress in hormonal therapy for advanced prostate cancer. Curr Opin Urol. 2006 May; 16(3):173-8. PMID: 16679855.
      View in: PubMed
    137. Daskivich TJ, Oh WK. Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms? Urology. 2006 May; 67(5):1084.e15-7. PMID: 16698377.
      View in: PubMed
    138. Mercer JS, Vohr BR, McGrath MM, Padbury JF, Wallach M, Oh W. Delayed cord clamping in very preterm infants reduces the incidence of intraventricular hemorrhage and late-onset sepsis: a randomized, controlled trial. Pediatrics. 2006 Apr; 117(4):1235-42. PMID: 16585320; PMCID: PMC1564438.
    139. Nakabayashi M, Oh WK. Chemotherapy for high-risk localized prostate cancer. BJU Int. 2006 Apr; 97(4):679-83. PMID: 16536752.
      View in: PubMed
    140. Febbo PG, Thorner A, Rubin MA, Loda M, Kantoff PW, Oh WK, Golub T, George D. Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer. Clin Cancer Res. 2006 Jan 1; 12(1):152-8. PMID: 16397037.
      View in: PubMed
    141. Rosenberg JE, Galsky MD, Rohs NC, Weinberg VK, Oh WK, Kelly WK, Small EJ. A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy. Cancer. 2006 Jan 1; 106(1):58-62. PMID: 16329138.
      View in: PubMed
    142. Oh W, Poindexter BB, Perritt R, Lemons JA, Bauer CR, Ehrenkranz RA, Stoll BJ, Poole K, Wright LL. Association between fluid intake and weight loss during the first ten days of life and risk of bronchopulmonary dysplasia in extremely low birth weight infants. J Pediatr. 2005 Dec; 147(6):786-90. PMID: 16356432.
      View in: PubMed
    143. Shankaran S, Laptook AR, Ehrenkranz RA, Tyson JE, McDonald SA, Donovan EF, Fanaroff AA, Poole WK, Wright LL, Higgins RD, Finer NN, Carlo WA, Duara S, Oh W, Cotten CM, Stevenson DK, Stoll BJ, Lemons JA, Guillet R, Jobe AH. Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy. N Engl J Med. 2005 Oct 13; 353(15):1574-84. PMID: 16221780.
      View in: PubMed
    144. Nakabayashi M, Regan MM, Lifsey D, Kantoff PW, Taplin ME, Sartor O, Oh WK. Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer. BJU Int. 2005 Oct; 96(6):783-6. PMID: 16153200.
      View in: PubMed
    145. Cotten CM, Oh W, McDonald S, Carlo W, Fanaroff AA, Duara S, Stoll B, Laptook A, Poole K, Wright LL, Goldberg RN. Prolonged hospital stay for extremely premature infants: risk factors, center differences, and the impact of mortality on selecting a best-performing center. J Perinatol. 2005 Oct; 25(10):650-5. PMID: 16079906.
      View in: PubMed
    146. Oh WK. High-risk localized prostate cancer: integrating chemotherapy. Oncologist. 2005 Oct; 10 Suppl 2:18-22. PMID: 16272455.
      View in: PubMed
    147. Febbo PG, Richie JP, George DJ, Loda M, Manola J, Shankar S, Barnes AS, Tempany C, Catalona W, Kantoff PW, Oh WK. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res. 2005 Jul 15; 11(14):5233-40. PMID: 16033841.
      View in: PubMed
    148. Van Meurs KP, Wright LL, Ehrenkranz RA, Lemons JA, Ball MB, Poole WK, Perritt R, Higgins RD, Oh W, Hudak ML, Laptook AR, Shankaran S, Finer NN, Carlo WA, Kennedy KA, Fridriksson JH, Steinhorn RH, Sokol GM, Konduri GG, Aschner JL, Stoll BJ, D'Angio CT, Stevenson DK. Inhaled nitric oxide for premature infants with severe respiratory failure. N Engl J Med. 2005 Jul 7; 353(1):13-22. PMID: 16000352.
      View in: PubMed
    149. Oh WK, George DJ, Tay MH. Response to docetaxel/carboplatin in patients with hormone-refractory prostate cancer not responding to taxane-based chemotherapy. Clin Prostate Cancer. 2005 Jun; 4(1):61-4. PMID: 15992464.
      View in: PubMed
    150. Galsky MD, Small EJ, Oh WK, Chen I, Smith DC, Colevas AD, Martone L, Curley T, Delacruz A, Scher HI, Kelly WK. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol. 2005 Mar 1; 23(7):1439-46. PMID: 15735119.
      View in: PubMed
    151. Lin HC, Su BH, Chen AC, Lin TW, Tsai CH, Yeh TF, Oh W. Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants. Pediatrics. 2005 Jan; 115(1):1-4. PMID: 15629973.
      View in: PubMed
    152. Oh WK, Hagmann E, Manola J, George DJ, Gilligan TD, Jacobson JO, Smith MR, Kaufman DS, Kantoff PW. A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer. Clin Cancer Res. 2005 Jan 1; 11(1):284-9. PMID: 15671557.
      View in: PubMed
    153. Ment LR, Vohr BR, Makuch RW, Westerveld M, Katz KH, Schneider KC, Duncan CC, Ehrenkranz R, Oh W, Philip AG, Scott DT, Allan WC. Prevention of intraventricular hemorrhage by indomethacin in male preterm infants. J Pediatr. 2004 Dec; 145(6):832-4. PMID: 15580211.
      View in: PubMed
    154. Oh WK. An overview of chemotherapy trials in localized and recurrent nonmetastatic prostate cancer. J Urol. 2004 Nov; 172(5 Pt 2):S34-7; discussion S37. PMID: 15535440.
      View in: PubMed
    155. Carroll PR, Chan JM, D'Amico AV, Gelmann EP, Iversen P, Klotz L, Nelson JB, Nelson PS, Nelson WG, Oh WK, Rosen N, Rubin MA, Sandler H, Sellers WR, Smith MR, Xu J, McMann MC, Kantoff PW. Fourth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment. J Urol. 2004 Nov; 172(5 Pt 2):S3-5. PMID: 15535434.
      View in: PubMed
    156. Smith MR, Manola J, Kaufman DS, George D, Oh WK, Mueller E, Slovin S, Spiegelman B, Small E, Kantoff PW. Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. Cancer. 2004 Oct 1; 101(7):1569-74. PMID: 15468186.
      View in: PubMed
    157. Nakabayashi M, Oh WK. Neoadjuvant and adjuvant chemotherapy for high-risk localized prostate cancer. Curr Treat Options Oncol. 2004 Oct; 5(5):349-55. PMID: 15341673.
      View in: PubMed
    158. Kaufman DS, Carducci MA, Kuzel TM, Todd MB, Oh WK, Smith MR, Ye Z, Nicol SJ, Stadler WM. A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer. Urol Oncol. 2004 Sep-Oct; 22(5):393-7. PMID: 15464919.
      View in: PubMed
    159. Oh WK, Kantoff PW, Weinberg V, Jones G, Rini BI, Derynck MK, Bok R, Smith MR, Bubley GJ, Rosen RT, DiPaola RS, Small EJ. Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol. 2004 Sep 15; 22(18):3705-12. PMID: 15289492.
      View in: PubMed
    160. Abe M, Manola JB, Oh WK, Parslow DL, George DJ, Austin CL, Kantoff PW. Plasma levels of heat shock protein 70 in patients with prostate cancer: a potential biomarker for prostate cancer. Clin Prostate Cancer. 2004 Jun; 3(1):49-53. PMID: 15279691.
      View in: PubMed
    161. George DJ, Regan MM, Oh WK, Tay MH, Manola J, Decalo N, Duggan S, Dewolf WC, Kantoff PW, Bubley GJ. Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer. Urology. 2004 Feb; 63(2):327-32. PMID: 14972483.
      View in: PubMed
    162. Liu G, Gandara DR, Lara PN, Raghavan D, Doroshow JH, Twardowski P, Kantoff P, Oh W, Kim K, Wilding G. A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer. Clin Cancer Res. 2004 Feb 1; 10(3):924-8. PMID: 14871968.
      View in: PubMed
    163. Oh WK, Halabi S, Kelly WK, Werner C, Godley PA, Vogelzang NJ, Small EJ. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. Cancer. 2003 Dec 15; 98(12):2592-8. PMID: 14669278.
      View in: PubMed
    164. Carroll PR, Benaron DA, Blackledge G, Coakley FV, D'Amico AV, Higano CS, Iversen P, Kattan M, Nanus DM, Nelson JB, Oh WK, Roach M, Sellers WR, Smith MR, McMann MC, Kantoff PW. Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatment. J Urol. 2003 Dec; 170(6 Pt 2):S3-5. PMID: 14610403.
      View in: PubMed
    165. Oh WK. The evolving role of chemotherapy and other systemic therapies for managing localized prostate cancer. J Urol. 2003 Dec; 170(6 Pt 2):S28-32; discussion S33-4. PMID: 14610407.
      View in: PubMed
    166. Leibowitz SB, Oh WK. Overtreatment of a patient with presumed recurrent prostate cancer based on false-positive prostate specific antigen results. J Urol. 2003 Oct; 170(4 Pt 1):1305. PMID: 14501750.
      View in: PubMed
    167. Oh W, Tyson JE, Fanaroff AA, Vohr BR, Perritt R, Stoll BJ, Ehrenkranz RA, Carlo WA, Shankaran S, Poole K, Wright LL. Association between peak serum bilirubin and neurodevelopmental outcomes in extremely low birth weight infants. Pediatrics. 2003 Oct; 112(4):773-9. PMID: 14523165.
      View in: PubMed
    168. Bhayani SB, Ong A, Oh WK, Kantoff PW, Kavoussi LR. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular cancer: a long-term update. Urology. 2003 Aug; 62(2):324-7. PMID: 12893344.
      View in: PubMed
    169. Oh WK, Manola J, Bittmann L, Brufsky A, Kaplan ID, Smith MR, Kaufman DS, Kantoff PW. Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up. Urology. 2003 Jul; 62(1):99-104. PMID: 12837431.
      View in: PubMed
    170. Oh WK, Kaplan ID, Febbo P, Prisby J, Manola J, Kaufman DS, Kantoff PW. Neoadjuvant doxil chemotherapy prior to androgen ablation plus radiotherapy for high-risk localized prostate cancer: feasibility and toxicity. Am J Clin Oncol. 2003 Jun; 26(3):312-6. PMID: 12796607.
      View in: PubMed
    171. Oh WK. Neoadjuvant therapy before radical prostatectomy in high-risk localized prostate cancer: defining appropriate endpoints. Urol Oncol. 2003 May-Jun; 21(3):229-34. PMID: 12810211.
      View in: PubMed
    172. Yu EY, Oh WK. Neoadjuvant therapy for high-risk localized prostate cancer. Curr Oncol Rep. 2003 May; 5(3):250-7. PMID: 12667424.
      View in: PubMed
    173. Leibowitz SB, Garber JE, Fox EA, Loda M, Kaufman DS, Kantoff PW, Oh WK. Male patients with diagnoses of both breast cancer and prostate cancer. Breast J. 2003 May-Jun; 9(3):208-12. PMID: 12752629.
      View in: PubMed
    174. Oh WK, Tully P, Kantoff PW, Regan MM. Physician attitudes toward cytotoxic chemotherapy use in patients with advanced prostate carcinoma. Cancer. 2003 May 1; 97(9):2171-9. PMID: 12712468.
      View in: PubMed
    175. Oh WK, Small EJ. Complementary and alternative therapies in prostate cancer. Semin Oncol. 2002 Dec; 29(6):575-84. PMID: 12516040.
      View in: PubMed
    176. Smith MR, Kaufman D, George D, Oh WK, Kazanis M, Manola J, Kantoff PW. Selective aromatase inhibition for patients with androgen-independent prostate carcinoma. Cancer. 2002 Nov 1; 95(9):1864-8. PMID: 12404279.
      View in: PubMed
    177. OH WK. Secondary hormonal therapies in the treatment of prostate cancer. Urology. 2002 Sep; 60(3 Suppl 1):87-92; discussion 93. PMID: 12231058.
      View in: PubMed
    178. Carlo WA, Stark AR, Wright LL, Tyson JE, Papile LA, Shankaran S, Donovan EF, Oh W, Bauer CR, Saha S, Poole WK, Stoll B. Minimal ventilation to prevent bronchopulmonary dysplasia in extremely-low-birth-weight infants. J Pediatr. 2002 Sep; 141(3):370-4. PMID: 12219057.
      View in: PubMed
    179. Oh WK. The evolving role of estrogen therapy in prostate cancer. Clin Prostate Cancer. 2002 Sep; 1(2):81-9. PMID: 15046698.
      View in: PubMed
    180. Carroll PR, Kantoff PW, Balk SP, Brown MA, D'amico AV, George DJ, Grossfeld GD, Johnson CS, Kelly WK, Klotz L, Lee WR, Lubeck DP, Mcleod DG, Oh WK, Pollack A, Sartor O, Smith MR, Hart C. Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. Urology. 2002 Sep; 60(3 Suppl 1):1-6. PMID: 12231036.
      View in: PubMed
    181. Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, Lemons JA, Donovan EF, Stark AR, Tyson JE, Oh W, Bauer CR, Korones SB, Shankaran S, Laptook AR, Stevenson DK, Papile LA, Poole WK. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics. 2002 Aug; 110(2 Pt 1):285-91. PMID: 12165580.
      View in: PubMed
    182. D'Amico AV, Saegaert T, Chen MH, Renshaw AA, George D, Oh W, Kantoff PW. Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer. Cancer. 2002 Jul 15; 95(2):275-80. PMID: 12124826.
      View in: PubMed
    183. Shankaran S, Papile LA, Wright LL, Ehrenkranz RA, Mele L, Lemons JA, Korones SB, Stevenson DK, Donovan EF, Stoll BJ, Fanaroff AA, Oh W, Verter J. Neurodevelopmental outcome of premature infants after antenatal phenobarbital exposure. Am J Obstet Gynecol. 2002 Jul; 187(1):171-7. PMID: 12114906.
      View in: PubMed
    184. Coyle MG, Ferguson A, Lagasse L, Oh W, Lester B. Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants. J Pediatr. 2002 May; 140(5):561-4. PMID: 12032522.
      View in: PubMed
    185. Oh WK, Loda M, Kantoff PW, Janicek M. Progressive sclerosis of isolated foot metastasis of prostate cancer. J Urol. 2002 Mar; 167(3):1392. PMID: 11832744.
      View in: PubMed
    186. Oh WK, Small EJ. PC-SPES and prostate cancer. Urol Clin North Am. 2002 Feb; 29(1):59-66, viii. PMID: 12109356.
      View in: PubMed
    187. Oh WK, George DJ, Kantoff PW. Rapid rise of serum prostate specific antigen levels after discontinuation of the herbal therapy PC-SPES in patients with advanced prostate carcinoma: report of four cases. Cancer. 2002 Feb 1; 94(3):686-9. PMID: 11857300.
      View in: PubMed
    188. Oh WK, Manola J, George DJ, Fierman A, Fontaine-Rothe P, Morrissey S, Prisby J, Kaufman DS, Shapiro CL, Kantoff PW, Smith MR. A phase II trial of interferon-alpha and toremifene in advanced renal cell cancer patients. Cancer Invest. 2002; 20(2):186-91. PMID: 11901538.
      View in: PubMed
    Back to TOP